Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.
carbocysteine
carbocysteine COPD
carbocysteine human diseases
carbocysteine lung diseases
carbocysteine pharmacology
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
14 Jun 2022
14 Jun 2022
Historique:
received:
07
04
2022
revised:
31
05
2022
accepted:
06
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with a versatile and complicated profile, being the fourth most common single cause of death worldwide. Several research groups have been trying to identify possible therapeutic approaches to treat COPD, such as the use of mucoactive drugs, which include carbocysteine. However, their role in the treatment of patients suffering from COPD remains controversial due to COPD's multifaceted profile. In the present review, 72 articles, published in peer-reviewed journals with high impact factors, are analyzed in order to provide significant insight and increase the knowledge about COPD considering the important contribution of carbocysteine in reducing exacerbations via multiple mechanisms. Carbocysteine is in fact able to modulate mucins and ciliary functions, and to counteract viral and bacterial infections as well as oxidative stress, offering cytoprotective effects. Furthermore, carbocysteine improves steroid responsiveness and exerts anti-inflammatory activity. This analysis demonstrates that the use of carbocysteine in COPD patients represents a well-tolerated treatment with a favorable safety profile, and might contribute to a better quality of life for patients suffering from this serious illness.
Identifiants
pubmed: 35745833
pii: pharmaceutics14061261
doi: 10.3390/pharmaceutics14061261
pmc: PMC9227620
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Dompé (Italy)
ID : NA
Références
J Mol Med (Berl). 2006 Jan;84(1):97-107
pubmed: 16283140
Br J Clin Pract. 1985 Oct;39(10):395-8
pubmed: 3907681
J Cell Physiol. 2017 Oct;232(10):2851-2859
pubmed: 27925185
Int Immunopharmacol. 2015 Feb;24(2):306-313
pubmed: 25533503
Eur J Pharmacol. 2002 Aug 2;449(1-2):183-9
pubmed: 12163123
Eur Respir J. 2016 Feb;47(2):625-37
pubmed: 26797035
Cell Physiol Biochem. 2008;22(5-6):455-64
pubmed: 19088427
J Med Microbiol. 2012 Jan;61(Pt 1):101-108
pubmed: 21890513
Pulm Pharmacol Ther. 2016 Aug;39:38-47
pubmed: 27328977
Br J Pharmacol. 2011 May;163(1):29-43
pubmed: 21198556
Microb Pathog. 2003 Jun;34(6):261-5
pubmed: 12782478
Cell Physiol Biochem. 2013;32(7):129-45
pubmed: 24429820
Respiration. 1996;63(3):174-80
pubmed: 8739489
Microb Pathog. 2001 Mar;30(3):121-7
pubmed: 11273737
Lancet. 2009 May 30;373(9678):1905-17
pubmed: 19482216
Pharmaceuticals (Basel). 2022 Feb 11;15(2):
pubmed: 35215330
Pflugers Arch. 2019 Feb;471(2):365-380
pubmed: 30291431
Toxicol Lett. 2013 Nov 25;223(2):198-204
pubmed: 24076166
Bull Eur Physiopathol Respir. 1976 Nov-Dec;12(6):771-9
pubmed: 1016804
Eur J Pharmacol. 2004 Mar 8;487(1-3):7-15
pubmed: 15033371
Eur J Pharmacol. 2012 Feb 29;677(1-3):173-9
pubmed: 22222820
Pharmacol Res. 1995 Jun;31(6):387-92
pubmed: 8685078
Int J Chron Obstruct Pulmon Dis. 2017 Aug 02;12:2277-2283
pubmed: 28814855
Lancet. 2008 Jun 14;371(9629):2013-8
pubmed: 18555912
Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6727-6735
pubmed: 31378916
Respirology. 2009 Sep;14(7):1027-34
pubmed: 19664007
Lancet. 2005 Apr 30-May 6;365(9470):1552-60
pubmed: 15866309
Clin Ther. 1982;4(6):480-8
pubmed: 7093981
COPD. 2017 Oct;14(5):552-563
pubmed: 28753070
J Clin Med. 2017 Nov 29;6(12):
pubmed: 29186064
Eur Respir Rev. 2010 Jun;19(116):109-12
pubmed: 20956178
Microbiol Immunol. 1999;43(2):107-13
pubmed: 10229264
Drug Des Devel Ther. 2019 Sep 16;13:3259-3268
pubmed: 31571828
Int Arch Allergy Immunol. 2004 Aug;134(4):273-80
pubmed: 15205558
Toxicol In Vitro. 2014 Mar;28(2):292-9
pubmed: 24269501
Nature. 2000 Aug 17;406(6797):782-7
pubmed: 10963608
Exp Gerontol. 2016 Aug;81:119-28
pubmed: 27237816
Eur J Pharmacol. 2004 Nov 28;505(1-3):169-75
pubmed: 15556150
Respir Physiol Neurobiol. 2012 Jan 15;180(1):112-8
pubmed: 22080978
Drug Metab Rev. 2012 May;44(2):129-47
pubmed: 22497630
FASEB J. 2013 Nov;27(11):4510-9
pubmed: 23934279
N Engl J Med. 2004 Mar 4;350(10):1005-12
pubmed: 14999112
Cell Stress Chaperones. 2013 Nov;18(6):733-43
pubmed: 23580157
Pharmacol Res. 2015 Jan;91:88-98
pubmed: 25500537
Am Rev Respir Dis. 1964 Jul;90:1-13
pubmed: 14178623
Thorax. 2019 Sep;74(9):898-905
pubmed: 31273049
Curr Med Res Opin. 1974;2(7):387-94
pubmed: 4615884
Eur Respir J. 1994 Sep;7(9):1622-8
pubmed: 7995391
Respir Med. 2020 May;166:105938
pubmed: 32250871
Chest. 2011 May;139(5):1101-1108
pubmed: 20847042
Thorax. 2006 May;61(5):448-54
pubmed: 16648353
Acta Pharmacol Sin. 2016 May;37(5):629-36
pubmed: 26997568
Open Access Maced J Med Sci. 2019 Dec 10;7(23):4030-4035
pubmed: 32165947
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Int J Chron Obstruct Pulmon Dis. 2017 Mar 22;12:803-812
pubmed: 28405161
Cochrane Database Syst Rev. 2019 May 20;5:CD001287
pubmed: 31107966
Eur Cytokine Netw. 2003 Jan-Mar;14(1):20-6
pubmed: 12799210
Eur Respir Rev. 2019 Mar 14;28(151):
pubmed: 30872396
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582
pubmed: 28128970
Eur J Pharmacol. 2010 Sep 1;641(2-3):226-8
pubmed: 20553908
Chest. 1976 Oct;70(4):506-13
pubmed: 789027
Immunology. 2008 Jul;124(3):401-11
pubmed: 18217953
Am J Physiol Lung Cell Mol Physiol. 2010 Aug;299(2):L160-8
pubmed: 20543005
Drug Intell Clin Pharm. 1988 Jul-Aug;22(7-8):603-8
pubmed: 3046890
Lancet. 2011 Sep 10;378(9795):1015-26
pubmed: 21907865
Pulm Pharmacol Ther. 2016 Apr;37:85-8
pubmed: 26970503
Drug Metab Dispos. 1982 Jan-Feb;10(1):61-2
pubmed: 6124385
Eur Respir J. 2006 Jul;28(1):51-8
pubmed: 16510461
Respirology. 2009 Jan;14(1):53-9
pubmed: 19144049
Int J Clin Pharmacol Res. 1985;5(5):331-40
pubmed: 4066083
Eur Respir Rev. 2010 Jun;19(116):134-40
pubmed: 20956182